A trip through the signaling pathways of melanoma;Ein streifzug durch die (signal-)wege des malignen melanoms

JDDG - Journal of the German Society of Dermatology

Volumn 4, Issue 3, 2006, Pages 205-216

  Fensterle, J ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Akt; B Raf kinase; Cell cycle; E cadherin; Metastasis; NF kappaB; p53

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; BETA CATENIN; CASPASE 3; CASPASE 8; CELECOXIB; CYCLINE; ERLOTINIB; GEFITINIB; GUANOSINE TRIPHOSPHATASE; HEAT SHOCK PROTEIN 90; INTEGRIN; INTERLEUKIN 8; MARIMASTAT; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN P53; PROTEIN TYROSINE KINASE; ROFECOXIB; SORAFENIB; TRASTUZUMAB; UVOMORULIN; VITRONECTIN RECEPTOR; WNT PROTEIN;

APOPTOSIS; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; DNA DAMAGE; DNA DEGRADATION; EXTRACELLULAR MATRIX; HEART INFARCTION; HUMAN; MALIGNANT TRANSFORMATION; MELANOMA; MELANOMA CELL; MITOGENESIS; MOLECULAR MODEL; MOLECULAR RECOGNITION; NONHUMAN; OLIGOMERIZATION; ONCOGENE; PATIENT MONITORING; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; STROKE; UNSPECIFIED SIDE EFFECT;

EID: 33645575146     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2006.05925.x     Document Type: Review

References (83)

1. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640-2653.
2. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
3. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
5. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001; 1: 222-231.
6. Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 2003; 3: 807-821.
7. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005; 5: 231-237.
8. Sieber OM, Heinimann K, Tomlinson IP. Genomic instability - the engine of tumorigenesis? Nat Rev Cancer 2003; 3: 701-708.
9. Maser RS, DePinho RA. Connecting chromosomes, crisis, and cancer. Science 2002; 297: 565-569.
10. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257.
11. Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 2003; 22: 6524-6536.
12. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 411: 342-348.
13. Dimova DK, Dyson NJ. The E2F transcriptional network: old acquaintances with new faces. Oncogene 2005; 24: 2810-2826.
14. Stevaux O, Dyson NJ. A revised picture of the E2F transcriptional network and RB function. Curr Opin Cell Biol 2002; 14: 684-691.
15. Li A, Blow JJ. The origin of CDK regulation. Nat Cell Biol 2001; 3: E182-184.
16. Pei XH, Xiong Y. Biochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues. Oncogene 2005; 24: 2787-2795.
17. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004; 432: 316-323.
18. Rossi D, Gaidano G. Messengers of cell death: apoptotic signaling in health and disease. Haematologica 2003; 88: 212-218.
19. Debatin KM. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother 2004; 53: 153-159.
20. Strasser A. The role of BH3-only proteins in the immune system. Nat Rev Immunol 2005; 5: 189-200.
21. Gray-Schopfer VC, da Rocha Dias S, Marais R. The role of B-RAF in melanoma. Cancer Metastasis Rev 2005; 24: 165-183.
22. Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004; 6: 447-458.
23. Houben R, Becker JC, Kappel A, Terheyden P, Brocker EB, Goetz R, Rapp UR. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 2004; 3: 6.
24. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002; 62: 6997-7000.
25. Wittbrodt J, Lammers R, Malitschek B, Ullrich A, Schartl M. The Xmrk receptor tyrosine kinase is activated in Xiphophorus malignant melanoma. Embo J 1992; 11: 4239-4246.
26. Bange J, Zwick E, Ullrich A. Molecular targets for breast cancer therapy and prevention. Nat Med 2001; 7: 548-552.
27. Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol 2005; 23: 3235-3242.
28. Becker JC, Schrama D, Brocker EB, Houben R. Kinase Inhibitoren für die Therapie des malignen Melanoms. J Dtsch Dermatol Ces 2005; 3: 762-767.
29. Cox AD, Der CJ. Ras family signaling: therapeutic targeting. Cancer Biol Ther 2002; 1: 599-606.
30. Robertson GP. Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev 2005; 24: 273-285.
31. Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW, Kester M, Sandirasegarane L, Robertson GP. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 2004; 64: 7002-7010.
32. Chen J, Somanath PR, Razorenova O, Chen WS, Hay N, Bornstein P, Byzova TV. Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat Med 2005; 11: 1188-1196.
33. Lawlor MA, Alessi DR. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 2001; 14: 2903-2910.
34. Millward TA, Zolnierowicz S, Hemmings BA. Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem Sci 1999; 24: 186-191.
35. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Pue J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-1947.
36. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003; 2: 1093-1103.
37. Dutcher JP. Mammalian target of rapamycin (mTOR) Inhibitors. Curr Oncol Rep 2004; 6: 111-115.
38. Dokmanovic M, Marks PA. Prospects: Histone deacetylase inhibitors. J Cell Biochem 2005; 96: 293-304.
39. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004; 432: 307-315.
40. Sherr CJ. Principles of tumor suppression. Cell 2004; 116: 235-246.
41. Sharpless E, Chin L. The INK4a/ARF locus and melanoma. Oncogene 2003; 22: 3092-3098.
42. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-848.
43. Voorhees PM, Orlowski RZ. The Proteasome and Proteasome Inhibitors in Cancer Therapy. Annu Rev Pharmacol Toxicol 2006; 46 (AOP, doi: 10.1146/annurev.pharmtox.46.120604.141300).
44. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005; 24: 2899-2908.
45. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-MYC as a target of the APC pathway. Science 1998; 281: 1509-1512.
46. Larue L, Kumasaka M, Goding CR. Beta-catenin in the melanocyte lineage. Pigment Cell Res 2003; 16: 312-317.
47. Mishra L, Shetty K, Tang Y, Stuart A, Byers SW. The role of TGF-beta and Wnt signaling in gastrointestinal stem cells and cancer. Oncogene 2005; 24: 5775-5789.
48. Weeraratna AT. A Wnt-er wonderland-the complexity of Wnt signaling in melanoma. Cancer Metastasis Rev 2005; 24: 237-250.
49. Behrens J, Jerchow BA, Wurtele M, Grimm J, Asbrand C, Wirtz R, Kuhl M, Wedlich D, Birchmeier W Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science 1998; 280: 596-599.
50. Raabe T, Rapp UR. KSR - a regulator and scaffold protein of the MAPK pathway. Sci STKE 2002; 2002: PE28.
51. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005; 5: 761-772.
52. Gumbiner BM. Regulation of cadherin-mediated adhesion in morphogenesis. Nat Rev Mol Cell Biol 2005; 6: 622-634.
53. Haass NK, Smalley KS, Li L, Herlyn M. Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res 2005; 18: 150-159.
54. Li G, Satyamoorthy K, Meier F, Berking C, Bogenrieder T, Herlyn M. Function and regulation of melanoma-stromal fibroblast interactions: when seeds meet soil. Oncogene 2003; 22: 3162-3171.
55. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 673-687.
56. Kuphal S, Bauer R, Bosserhoff AK. Integrin signaling in malignant melanoma. Cancer Metastasis Rev 2005; 24: 195-222.
57. Hofmann UB, Westphal JR, Waas ET, Becker JC, Ruiter DJ, van Muijen GN. Coexpression of integrin alpha(v) beta3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: correlation with melanoma progression. J Invest Dermatol 2000; 115: 625-632.
58. Hsu MY, Shih DT, Meier FE, Van Belle P, Hsu JY, Elder DE, Buck CA, Herlyn M. Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol 1998; 153: 1435-1442.
59. Hofmann UB, Houben R, Brocker EB, Becker JC. Role of matrix metalloproteinases in melanoma cell invasion. Biochimie 2005; 87: 307-314.
60. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003; 3: 362-374.
61. Sparano JA, Bernardo P, Stephenson P, Gradishar WJ, Ingle JN, Zucker S, Davidson NE. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol 2004; 22: 4683-4690.
62. Mantovani A, Allavena P, Sica A. Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer 2004; 40: 1660-1667.
63. Schwartsburd PM. Chronic inflammation as inductor of pro-cancer microenvironment: pathogenesis of dysregulated feedback control. Cancer Metastasis Rev 2003; 22: 95-102.
64. Blankenstein T. The role of inflammation in tumour growth and tumour suppression. Novartis Found Symp 2004; 256: 205-210.
65. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867.
66. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749-759.
67. Li Q, Withoff S, Verma IM. Inflammation-associated cancer: NF-kappaB is the lynchpin. Trends Immunol 2005; 26: 318-325.
68. Amiri KI, Richmond A. Role of nuclear factor-kappa B in melanoma. Cancer Metastasis Rev 2005; 24: 301-313.
69. Troppmair J, Hartkamp J, Rapp UR. Activation of NF-kappa B by oncogenic Raf in HEK 293 cells occurs through autocrine recruitment of the stress kinase cascade. Oncogene 1998; 17: 685-690.
70. Wajant H, Henkler F, Scheurich P. The TNF-receptor-associated factor family: scaffold molecules for cytokine receptors, kinases and their regulators. Cell Signal 2001; 13: 389-400.
71. Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 1997; 39: 1-20.
72. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94: 252-266.
73. Thun MJ, Namboodiri MM, Heath CW, Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593-1596.
74. Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, Loar A, Rodabough RJ, White E, McTiernan A. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 2003; 63: 6096-6101.
75. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364: 2021-2029.
76. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365: 475-481.
77. Bresalier RS, Sandier RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA; Adenomatous Polyp Prevention on Vioxx (AP-PROVc) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-1102.
78. Vogelstein B, Kinzler KW Cancer genes and the pathways they control. Nat Med 2004; 10: 789-799.
79. Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. Nat Rev Drug Discov 2003; 2: 803-811.
80. Wetmore C. Sonic hedgehog in normal and neoplastic proliferation: insight gained from human tumors and animal models. Curr Opin Genet Dev 2003; 13: 34-42.
81. Sharpless NE, DePinho RA. Cancer: crime and punishment. Nature 2005; 436: 636-637.
82. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW Mooi WJ, Peeper DS. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005; 436: 720-724.
83. Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev 2004; 18: 2699-2711.